Replagal Approval Status
- FDA approved: No
- Brand name: Replagal
- Generic name: agalsidase alfa
- Company: Shire plc
- Treatment for: Fabry Disease
Replagal (agalsidase alfa) is an enzyme replacement therapy in development for Fabry disease.
Development Status and FDA Approval Process for Replagal
|Dec 22, 2009||Shire Submits Biologics License Application for Replagal With the U.S. Food and Drug Administration|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.